Status:
RECRUITING
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Lung Neoplasms
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combin...
Detailed Description
Conventional 18F-FDG PET/CT has important diagnostic value in cell metabolism level, early metastasis, judging malignant potential and prognosis of tumors. It has been routinely used for staging and r...
Eligibility Criteria
Inclusion Criteria:
- patients with confirmed or suspected lung cancer;
- 68Ga-FAPI-RGD and 18F-FDG(or 68Ga-FAPI or 68Ga-RGD) PET/CT within 2 week;
- signed written consent.
Exclusion Criteria:
- pregnancy;
- breastfeeding;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
September 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05543954
Start Date
September 3 2022
End Date
December 31 2025
Last Update
July 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, China